238 related articles for article (PubMed ID: 22031860)
1. Engineered factor IX variants bypass FVIII and correct hemophilia A phenotype in mice.
Milanov P; Ivanciu L; Abriss D; Quade-Lyssy P; Miesbach W; Alesci S; Tonn T; Grez M; Seifried E; Schüttrumpf J
Blood; 2012 Jan; 119(2):602-11. PubMed ID: 22031860
[TBL] [Abstract][Full Text] [Related]
2. Next generation FIX muteins with FVIII-independent activity for alternative treatment of hemophilia A.
Quade-Lyssy P; Abriss D; Milanov P; Ungerer C; Königs C; Seifried E; Schüttrumpf J
J Thromb Haemost; 2014 Nov; 12(11):1861-73. PubMed ID: 25224783
[TBL] [Abstract][Full Text] [Related]
3. Hemophilia A and B mice, but not VWF
Taves S; Sun J; Livingston EW; Chen X; Amiaud J; Brion R; Hannah WB; Bateman TA; Heymann D; Monahan PE
Sci Rep; 2019 Oct; 9(1):14428. PubMed ID: 31594977
[TBL] [Abstract][Full Text] [Related]
4. A factor IX variant that functions independently of factor VIII mitigates the hemophilia A phenotype in patient plasma.
Strijbis VJF; Romano LGR; Cheung KL; Eikenboom J; Liu YP; McCreary AC; Leebeek FWG; Bos MHA
J Thromb Haemost; 2023 Jun; 21(6):1466-1477. PubMed ID: 36863564
[TBL] [Abstract][Full Text] [Related]
5. FIXing factor VIII inhibitors.
Ponder KP
Blood; 2012 Jan; 119(2):325-6. PubMed ID: 22247519
[No Abstract] [Full Text] [Related]
6. A hemophilia A mouse model for the in vivo assessment of emicizumab function.
Ferrière S; Peyron I; Christophe OD; Kawecki C; Casari C; Muczynski V; Nathwani A; Kauskot A; Lenting PJ; Denis CV
Blood; 2020 Aug; 136(6):740-748. PubMed ID: 32369559
[TBL] [Abstract][Full Text] [Related]
7. Hemophilia Gene Therapy: Ready for Prime Time?
VandenDriessche T; Chuah MK
Hum Gene Ther; 2017 Nov; 28(11):1013-1023. PubMed ID: 28793786
[TBL] [Abstract][Full Text] [Related]
8. Expression and characterization of a novel human recombinant factor IX molecule with enhanced in vitro and in vivo clotting activity.
Perot E; Enjolras N; Le Quellec S; Indalecio A; Girard J; Negrier C; Dargaud Y
Thromb Res; 2015 May; 135(5):1017-24. PubMed ID: 25795563
[TBL] [Abstract][Full Text] [Related]
9. Novel factor VIII variants with a modified furin cleavage site improve the efficacy of gene therapy for hemophilia A.
Nguyen GN; George LA; Siner JI; Davidson RJ; Zander CB; Zheng XL; Arruda VR; Camire RM; Sabatino DE
J Thromb Haemost; 2017 Jan; 15(1):110-121. PubMed ID: 27749002
[TBL] [Abstract][Full Text] [Related]
10. Incorporation of the factor IX Padua mutation into FIX-Triple improves clotting activity in vitro and in vivo.
Kao CY; Yang SJ; Tao MH; Jeng YM; Yu IS; Lin SW
Thromb Haemost; 2013 Aug; 110(2):244-56. PubMed ID: 23676890
[TBL] [Abstract][Full Text] [Related]
11. Employing a gain-of-function factor IX variant R338L to advance the efficacy and safety of hemophilia B human gene therapy: preclinical evaluation supporting an ongoing adeno-associated virus clinical trial.
Monahan PE; Sun J; Gui T; Hu G; Hannah WB; Wichlan DG; Wu Z; Grieger JC; Li C; Suwanmanee T; Stafford DW; Booth CJ; Samulski JJ; Kafri T; McPhee SW; Samulski RJ
Hum Gene Ther; 2015 Feb; 26(2):69-81. PubMed ID: 25419787
[TBL] [Abstract][Full Text] [Related]
12. A novel therapeutic approach combining human plasma-derived Factors VIIa and X for haemophiliacs with inhibitors: evidence of a higher thrombin generation rate in vitro and more sustained haemostatic activity in vivo than obtained with Factor VIIa alone.
Tomokiyo K; Nakatomi Y; Araki T; Teshima K; Nakano H; Nakagaki T; Miyamoto S; Funatsu A; Iwanaga S
Vox Sang; 2003 Nov; 85(4):290-9. PubMed ID: 14633255
[TBL] [Abstract][Full Text] [Related]
13. Phenotypic correction and long-term expression of factor VIII in hemophilic mice by immunotolerization and nonviral gene transfer using the Sleeping Beauty transposon system.
Ohlfest JR; Frandsen JL; Fritz S; Lobitz PD; Perkinson SG; Clark KJ; Nelsestuen G; Key NS; McIvor RS; Hackett PB; Largaespada DA
Blood; 2005 Apr; 105(7):2691-8. PubMed ID: 15576475
[TBL] [Abstract][Full Text] [Related]
14. Factor IX ectopically expressed in platelets can be stored in alpha-granules and corrects the phenotype of hemophilia B mice.
Zhang G; Shi Q; Fahs SA; Kuether EL; Walsh CE; Montgomery RR
Blood; 2010 Aug; 116(8):1235-43. PubMed ID: 20445020
[TBL] [Abstract][Full Text] [Related]
15. Gene therapy for the hemophilias.
VandenDriessche T; Collen D; Chuah MK
J Thromb Haemost; 2003 Jul; 1(7):1550-8. PubMed ID: 12871290
[TBL] [Abstract][Full Text] [Related]
16. Perspectives on the use of factor IX complex concentrates in the treatment of bleeding in persons with acquired factor VIII inhibition.
Lusher JM
Am J Med; 1991 Nov; 91(5A):30S-34S. PubMed ID: 1746594
[TBL] [Abstract][Full Text] [Related]
17. Platelet and endothelial expression of clotting factors for the treatment of hemophilia.
Montgomery RR; Shi Q
Thromb Res; 2012 May; 129 Suppl 2(Suppl 2):S46-8. PubMed ID: 22421106
[TBL] [Abstract][Full Text] [Related]
18. A microRNA-regulated and GP64-pseudotyped lentiviral vector mediates stable expression of FVIII in a murine model of Hemophilia A.
Matsui H; Hegadorn C; Ozelo M; Burnett E; Tuttle A; Labelle A; McCray PB; Naldini L; Brown B; Hough C; Lillicrap D
Mol Ther; 2011 Apr; 19(4):723-30. PubMed ID: 21285959
[TBL] [Abstract][Full Text] [Related]
19. Gene Delivery of Activated Factor VII Using Alternative Adeno-Associated Virus Serotype Improves Hemostasis in Hemophiliac Mice with FVIII Inhibitors and Adeno-Associated Virus Neutralizing Antibodies.
Sun J; Hua B; Chen X; Samulski RJ; Li C
Hum Gene Ther; 2017 Aug; 28(8):654-666. PubMed ID: 28478688
[TBL] [Abstract][Full Text] [Related]
20. A sensitive venous bleeding model in haemophilia A mice: effects of two recombinant FVIII products (N8 and Advate(®)).
Pastoft AE; Lykkesfeldt J; Ezban M; Tranholm M; Whinna HC; Lauritzen B
Haemophilia; 2012 Sep; 18(5):782-8. PubMed ID: 22500820
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
